E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas
TL;DR: Single-agent Inotuzumab ozogamicin has demonstrated activity in patients with relapsed B-cell ALL and non-Hodgkin lymphoma and there is potential for IO to be combined with other targeted therapies under development for these diseases.
Journal Article
Optimal first-line treatment of chronic myeloid leukemia: How to use imatinib and what role for newer drugs?
TL;DR: There are an increasing number of treatment options now available for patients with CML, and the understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance.
Journal ArticleDOI
Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.
Hagop M. Kantarjian,Elias Jabbour,Francis J. Giles,Kapil N. Bhalla,Javier Pinilla-Ibarz,Richard A. Larson,Norbert Gattermann,Oliver G. Ottmann,Jim Wang,Richard C. Woodman,Michele Baccarani,Philipp le Coutre,Jorge E. Cortes +12 more
TL;DR: The preliminary results of this multivariate analysis of 21 disease or response factors identified 4 factors that predict for PFS in imatinib-resistant and -intolerant patients receiving nilotinib therapy in this large dataset.
Journal ArticleDOI
Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis
Rashmi Kanagal-Shamanna,Guillermo Montalban Bravo,Panagiotis Katsonis,Koji Sasaki,Caleb A. Class,Christopher B. Benton,Elias Jabbour,Kelly S. Chien,Rajyalakshmi Luthra,Carlos E. Bueso-Ramos,Tapan M. Kadia,Michael Andreeff,Nicholas J. Short,Naval Daver,Mark J. Routbort,Joseph D. Khoury,Keyur P. Patel,Irene Ganan-Gomez,Yue Wei,Gautam Borthakur,Farhad Ravandi,Kim Anh Do,Kelly A. Soltysiak,Olivier Lichtarge,L. Jeffrey Medeiros,Hagop M. Kantarjian,Guillermo Garcia-Manero +26 more
TL;DR: The deleterious effects of missense TP53MT associated with OS <10 months were quantified using the computationally-derived evolutionary action score (EAp53, range, 0-100, higher score indicates worse impact), followed by 3D protein mapping to identify prognostic subsets.
Journal ArticleDOI
Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience
Mansour Alfayez,Hagop M. Kantarjian,Nicholas J. Short,Rita Assi,Maria Khouri,Farhad Ravandi,Shilpa Paul,Caitlin R. Rausch,Patrice Nasnas,Gautam Borthakur,Courtney D. DiNardo,Tapan M. Kadia,Naval Daver,Guillermo Garcia-Manero,Kiran Naqvi,Prithviraj Bose,Susan O'Brien,Jorge E. Cortes,Elias Jabbour +18 more
TL;DR: The combination of blinatumomab with CNS directed therapy is safe and effective in patients with active CNS disease, particularly when given in combination with systemic and intrathecal chemotherapy.